BST | Jotup

Maravai LifeSciences Hosts 2023 Investor R&D Day

Retrieved on:

Friday, September 29, 2023

Workforce, GMP, CRISPR, Intellectual property, Melamaravakkadu, Probability, Therapy, D, RNA, NAP, Chemistry, EBITDA, SAN, Drug discovery, Growth, BST, Management, Fine chemical

SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, hosted its 2023 Investor R&D Day featuring presentations by Trey Martin, Chief Executive Officer, and other members of the Maravai leadership team that showcased the company’s strong foundation for growth, key differentiators, innovations, and attractive long-term growth outlook.

Key Points:

SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, hosted its 2023 Investor R&D Day featuring presentations by Trey Martin, Chief Executive Officer, and other members of the Maravai leadership team that showcased the company’s strong foundation for growth, key differentiators, innovations, and attractive long-term growth outlook.
“Maravai has established an exceptionally strong foundation and we are building momentum toward our long-term goal of achieving high teens revenue growth with expanding EBITDA margins,” said Trey Martin, CEO of Maravai LifeSciences.
At the leadership level, Maravai has assembled an extraordinary team of executives with robust life sciences expertise and proven ability to lead.
We are targeting $700M in revenue and > 40% adjusted EBITDA in 2028, representing an ~18% CAGR from 2023 to 2028.

Open XR Forum to Host Symposium on the Latest Specifications and Use Cases of Intelligent Coherent Pluggables at ECOC 2023

Retrieved on:

Thursday, September 28, 2023

Infinera, Airway transportation systems specialist, Open, PON, TIM, European Conference on Computational Biology, SAN, Verizon Communications, ECOC, Conference, Technical, BST, Tissue paper

SAN JOSE, Calif., Sept. 28, 2023 /PRNewswire/ -- Open XR Forum announced today that it will host a symposium on October 3 at the European Conference on Optical Communication (ECOC).

Key Points:

SAN JOSE, Calif., Sept. 28, 2023 /PRNewswire/ -- Open XR Forum announced today that it will host a symposium on October 3 at the European Conference on Optical Communication (ECOC).
The symposium, open to all attendees, will be held at the ECOC Exhibition 2023 SEC – Product Focus Area, Hall 3 in Glasgow, Scotland, from 10:00 a.m. – 11:30 a.m. BST.
This symposium will feature the latest transceiver specifications, including thermal mechanical form factor and electro-optical characteristics.
The symposium will also highlight multi-vendor use cases, including full-featured host-independent management, multipoint aggregation, and high-speed business services over passive optical network (PON) infrastructures.

Renalytix Reports Full Year Fiscal 2023 Results

Retrieved on:

Thursday, September 28, 2023

LONDON and SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, reports its financial results for the fiscal year ended June 30, 2023.

Key Points:

LONDON and SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, reports its financial results for the fiscal year ended June 30, 2023.
Deployment and risk stratification by KidneyIntelX was associated with escalation in clinical actions taken to optimize cardio-metabolic-kidney health including medications and referrals.
Over 5,000 KidneyIntelX tests performed in fiscal year 2023, up 55% from the prior year
Investors are advised to read the results for the 12 months ended 30 June 2023, which have been filed with the U.S. Securities and Exchange Commission on Form 10-K concurrently with this results announcement.
Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.

Interim Results for the Six Months Ended 30 June 2023

Retrieved on:

Wednesday, September 27, 2023

LSE, Q&A, Biotechnology, Harpoon, Sustainability Accounting Standards Board, Therapy, BST, Cryptocurrency, Security (finance), Powerscourt

LONDON, 27 September 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces its interim results for the six months ended 30 June 2023.

Key Points:

LONDON, 27 September 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces its interim results for the six months ended 30 June 2023.
“Following the announcement of the strategic review in July 2023, the Board has been exploring a range of strategic options for the Company.
Currently, a number of options remain under active consideration and the Board is focused on evaluating these in conjunction with its advisers.
Analysts wishing to join should register their interest by contacting Powerscourt on [email protected] or on +44 (0) 20 7290 1050.

Ardagh Metal Packaging S.A. Q3 2023 Results and Investor Call Notification

Retrieved on:

Tuesday, September 26, 2023

BST, Cryptocurrency

LUXEMBOURG, Sept. 26, 2023 /PRNewswire/ -- Ardagh Metal Packaging S.A. will host its Third Quarter 2023 earnings call on Thursday, October 26, 2023.

Key Points:

LUXEMBOURG, Sept. 26, 2023 /PRNewswire/ -- Ardagh Metal Packaging S.A. will host its Third Quarter 2023 earnings call on Thursday, October 26, 2023.
A results release will be posted to our website at midday BST (07:00 EDT) on October 26, 2023, at https://www.ardaghmetalpackaging.com/investors
An investor webcast and conference call will be held at 14:00 BST (9:00 EDT) on October 26, 2023.
A full replay of the presentation will also be available at the same link shortly after the conclusion of the live presentation.

Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28

Retrieved on:

Monday, September 25, 2023

Telephone, LSE, PIN, SALT, BST, Cryptocurrency, Security (finance)

LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday, September 28, 2023, before market open.

Key Points:

LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday, September 28, 2023, before market open.
The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST).
To participate in the live conference call via telephone, please register here .
Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.

Alphawave IP Group plc Interim Results for the Six Months Ended 30 June 2023

Retrieved on:

Monday, September 25, 2023

In H1 2023 we delivered a good set of results, scaling our business and investing organically to support our pipeline and future revenue growth.

Key Points:

In H1 2023 we delivered a good set of results, scaling our business and investing organically to support our pipeline and future revenue growth.
Long-term waiver obtained from lenders covering the period to 30 June 2024
Cash and cash equivalents of US$122.8m.
To register for the webcast:
After registering, you will receive a confirmation email with information about joining the webcast.
The Company's H1 2023 Report is also available to view in the Investor Relations section of the Company’s website ( Results, Reports & Presentations (awaveip.com) ).

Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

Retrieved on:

Thursday, September 21, 2023

Webcast, Fireside chats, Conference, Fireside, BST, Rare-earth element, Broadcasting

LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 10:55am ET / 03:55pm BST.

Key Points:

LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 10:55am ET / 03:55pm BST.
A live audio webcast of the presentation can be accessed through the Investors section of the Company’s website at www.mereobiopharma.com/investors .
An archived replay of the webcast will be available on the Company’s website for two weeks following the live event.

Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023

Retrieved on:

Wednesday, September 20, 2023

Dr. Frank Mathias, Oxford Biomedica’s Chief Executive Officer, said:

Key Points:

Dr. Frank Mathias, Oxford Biomedica’s Chief Executive Officer, said:
“Oxford Biomedica is a market leader in the fast-growing gene and cell therapy market.
I value our staff tremendously and thank everyone for their hard work and contribution to Oxford Biomedica both now and into the future.
Cash at 30 June 2023 was 9% higher at £129.4 million compared to £118.5 million at 30 June 2022.
The net cash position was 16% higher at £90.1 million as of 30 June 2023 (30 June 2022: £78.7 million).

CMR Surgical surpasses 15,000 surgical procedures on Versius® globally as it raises $165 million to support continued growth

Retrieved on:

Wednesday, September 20, 2023

The company has recently closed an upsized $165 million (£133 million) fundraising to support continued product innovation and commercial growth in existing and key new markets around the world.

Key Points:

The company has recently closed an upsized $165 million (£133 million) fundraising to support continued product innovation and commercial growth in existing and key new markets around the world.
CMR Surgical (CMR or ‘the Company’) – the global surgical robotics business – has today announced that its next-generation Versius® Surgical Robotic System has been used to perform more than 15,000 surgeries globally.
The surgical cases span more than 130 complex and benign procedure types including colectomies, hernia repairs, hysterectomies, sacrocolpopexies, and lobectomies across seven surgical specialties.
CMR’s vision is to make MAS universally accessible, rapidly increasing the number of robotic-assisted procedures that take place globally.